Metabolic Dysfunction-Associated Steatohepatitis (MASH) is becoming a leading cause of liver dysfunction, affecting over 20 million Americans. However, identifying at-risk patients and studying disease progression remains challenging. In this webinar, Dr. Cassie Hajek from Helix and Dr. Joseph Grzymski from Renown Health discuss how they're leveraging large-scale clinical and genomic data to advance MASH research.
Key topics covered:
- Building targeted cohorts using extensive inclusion and exclusion criteria
- Integrating clinical data with whole exome sequencing information
- Scaling research across the Helix Research Network
- Potential applications beyond MASH to other cardiometabolic conditions
- Future directions for improving non-invasive testing and predictive modeling
Learn how this approach could revolutionize our understanding of complex diseases and lead to more personalized treatment strategies.
Speakers:
- Cassie Hajek, MD, Medical Director, Helix
- Joseph Grzymski, PhD, Chief Scientific Officer, Renown Health